Thymosin Alpha-1 vs LL-37
Side-by-side comparison of Thymosin Alpha-1, LL-37 — mechanism, dosing, half-life, side effects, and research status.
| Attribute | Thymosin Alpha-1 Thymosin Alpha-1 (Tα1) Longevity | LL-37 LL-37 (Human Cathelicidin Antimicrobial Peptide) Recovery |
|---|---|---|
| Basics | ||
| Molecular type | Thymic Peptide | Human Cathelicidin |
| Amino acids | 28 | 37 |
| Molecular weight | 3,108.4 Da | 4,493.3 Da |
| Half-life | ~2 hours | Short (hours) |
| Route(s) | Subcutaneous | Subcutaneous, Topical, Intranasal |
| Mechanism & Research | ||
| Primary mechanism | Thymosin Alpha-1 stimulates T-cell differentiation and maturation, particularly enhancing T-helper cell (Th1) responses. This drives improved cell-mediated immunity — the arm of the immune system responsible for clearing… | LL-37 disrupts microbial membranes through electrostatic interaction — its cationic amphipathic helical structure inserts into negatively charged bacterial membranes, causing lethal membrane permeabilisation. This mechan… |
| Research status | Research Compound | Research Compound |
| Evidence summary | Thymosin Alpha-1 has extensive human clinical data from its regulatory approval in Asia and Europe for viral hepatitis and cancer adjunct therapy. Longevity applications build on this established safety and immune-modula… | LL-37 has been studied extensively for wound healing, respiratory infections (including COVID-19 lung immunity), and more recently for senolytic applications. Its broad antimicrobial and immunomodulatory profile makes it… |
| Protocol & Dosing | ||
| Typical dose | 1.6 mg per injection (standard clinical dose) | 1–5 mg per injection or topical application |
| Frequency | 2x per week for 6–12 weeks | Daily |
| Duration | 6–12 weeks | 4–8 weeks |
| Timing | Any time of day | Any time |
| Safety | ||
| Common side effects |
|
|
| Contraindications |
|
|
| Anti-doping | Not Prohibited | Not Prohibited |
| Deeper reading | ||
| Related peptides | Epithalon, TB-500, LL-37 | BPC-157, GHK-Cu, KPV |
| Full profile | Read full Thymosin Alpha-1 profile → | Read full LL-37 profile → |
Comparison data is compiled from each peptide’s individual profile. All values are drawn from peer-reviewed research and regulatory sources. For educational use only — not medical advice. Verify any protocol with a qualified healthcare provider.